Clinical Trial Update: A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL [Phase 2]

View source ↗

Summary

Clinical trial update for a Phase 2 study of polatuzumab vedotin with rituximab and dose-attenuated CHP in older patients with diffuse large B-cell lymphoma; th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Rituximab (rituximab)
• polatuzumab vedotin (polatuzumab vedotin)

Snippet

Sponsor: University of Rochester | Conditions: DLBCL, Lymphoma, B-Cell | Phase 2 | Status: ACTIVE_NOT_RECRUITING